Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 05-13 12:49:05 EDT

13.05

-0.47

-3.48%

High13.82	Low12.97	Vol50.35K
Open13.53	D1 Closing13.52	Amplitude6.29%
Mkt Cap647.91M	Tradable Cap300.10M	Total Shares49.65M
T/O673.30K	T/O Rate0.22%	Tradable Shares23.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":13.05,"timestamp":1715618929813,"preClose":13.52,"halted":0,"volume":50351,"delay":0,"floatShares":22996344,"shares":49648540,"eps":-2.202641,"marketStatus":"Trading","change":-0.47,"latestTime":"05-13 12:49:05 EDT","open":13.53,"high":13.82,"low":12.97,"amount":673299.009908,"amplitude":0.06287,"askPrice":13.06,"askSize":606,"bidPrice":13.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.202641,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715630400000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":13.52,"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"16:02 EDT","volume":997,"amount":13479.44,"timestamp":1715371340201},"volumeRatio":0.328191},"requestUrl":"/m/hq/s/MLYS","defaultTab":"news","newsList":[{"id":"2434601157","title":"Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434601157","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434601157?lang=en_us&edition=fundamental","pubTime":"2024-05-09 23:10","pubTimestamp":1715267412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424209","title":"Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424209","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433424209?lang=en_us&edition=fundamental","pubTime":"2024-05-06 20:00","pubTimestamp":1714996800,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., May 06, 2024  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease  and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.Media RelationsTom WeibleElixir Health Public RelationsPhone:  515-707-9678Email: tweible@elixirhealthpr.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-participate-bank-america-120000770.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432672265","title":"Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672265","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432672265?lang=en_us&edition=fundamental","pubTime":"2024-05-02 12:00","pubTimestamp":1714622400,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., May  02, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874160/0/en/Mineralys-Therapeutics-to-Announce-First-Quarter-2024-Financial-Results-and-Host-Conference-Call-on-Thursday-May-9-2024.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424702395","title":"Mineralys Therapeutics Board Member Announces Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2424702395","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424702395?lang=en_us&edition=fundamental","pubTime":"2024-04-04 20:12","pubTimestamp":1712232752,"startTime":"0","endTime":"0","summary":"The latest update is out from Mineralys Therapeutics, Inc. (MLYS). Alexander Asam, Ph.D., has announced he will step down from the Board of Directo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-board-member-announces-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-board-member-announces-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424866509","title":"What To Buy After You Sell The Russell 2000","url":"https://stock-news.laohu8.com/highlight/detail?id=2424866509","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424866509?lang=en_us&edition=fundamental","pubTime":"2024-04-03 15:07","pubTimestamp":1712128072,"startTime":"0","endTime":"0","summary":"Despite the case for small caps, it is recommended to sell the Russell 2000 and related ETFs due to negative alpha and seasonal factors.The S&P 600 and the CRSP Small Cap Index do not suffer from the ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221962008/image_1221962008.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221962008/image_1221962008.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4681871-what-to-buy-after-you-sell-the-russell-2000","is_publish_highlight":false,"gpt_icon":0},{"id":"2424752460","title":"Goldman starts Mineralys at buy, cites upcoming drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2424752460","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424752460?lang=en_us&edition=fundamental","pubTime":"2024-04-03 02:37","pubTimestamp":1712083031,"startTime":"0","endTime":"0","summary":"Goldman Sachs has initiated coverage of Mineralys Therapeutics  with a buy rating, citing upcoming data for its hypertension drug candidate lorundrostat. The investment bank said it believes the company could attract “considerable” partnership interest if it has a successful data readout for the drug from a Phase 2 study called Advance-HTN. The data is expected in Q4. Goldman said it sees lorundrostat achieving worldwide non-risk-adjusted peak sales of approximately $2.8B or risk-adjusted peak sales of around $1.1B in 2040. It added that its buy rating was being driven primarily by the company “potentially showing best-in-class efficacy in a large obesity-related hypertension market.” Goldman set its price target for the stock at $30.  More on Mineralys Therapeutics  Mineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Mineralys Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Mineralys Therapeutics: A Story To Keep An Eye On QuidelOrtho stock falls 11% on Sa","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1015828796/image_1015828796.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1015828796/image_1015828796.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086537-goldman-starts-mineralys-at-buy-cites-upcoming-drug-data","is_publish_highlight":false,"gpt_icon":0},{"id":"2424078556","title":"QuidelOrtho stock falls 11% on Savanna PVP4+ assay update","url":"https://stock-news.laohu8.com/highlight/detail?id=2424078556","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424078556?lang=en_us&edition=fundamental","pubTime":"2024-04-03 02:01","pubTimestamp":1712080872,"startTime":"0","endTime":"0","summary":"QuidelOrtho (NASDAQ:QDEL) stock dropped 11% in afternoon trading Tuesday after the medtech company said it has pulled the FDA market application for its Savanna RVP4+ assay due to data concerns.  Quid","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086530-quidelortho-stock-falls-on-savanna-pvp4-assay-update","is_publish_highlight":false,"gpt_icon":0},{"id":"2421843517","title":"Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2421843517","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2421843517?lang=en_us&edition=fundamental","pubTime":"2024-03-22 22:51","pubTimestamp":1711119065,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.85. MLYS isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter .Daniel Ferry: Thank you, operator. Good morning, everyone, and welcome to our fourth quarter and full year 2023 conference call. Earlier this morning, we issued a press release providing our fourth quarter and full year 2023 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately 1 hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.In 2024, we're working towards ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5phrKJC5k6ZepO_mQAlISA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7842e5338fe3f58414eef4d434f8f144","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5phrKJC5k6ZepO_mQAlISA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7842e5338fe3f58414eef4d434f8f144"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-inc-nasdaq-mlys-145105689.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421864824","title":"Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2421864824","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2421864824?lang=en_us&edition=fundamental","pubTime":"2024-03-22 17:20","pubTimestamp":1711099256,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Resmed (RMD – Research Report), Mineralys Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-mineralys-therapeutics-inc-mlys-and-addus-homecare-adus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-resmed-rmd-mineralys-therapeutics-inc-mlys-and-addus-homecare-adus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2421232180","title":"Mineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2421232180","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421232180?lang=en_us&edition=fundamental","pubTime":"2024-03-21 23:48","pubTimestamp":1711036091,"startTime":"0","endTime":"0","summary":"The following slide deck was published by Mineralys Therapeutics, Inc. in conjunction with their 2023 Q4 earnings call.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4679670-mineralys-therapeutics-inc-2023-q4-results-earnings-call-presentation","is_publish_highlight":false,"gpt_icon":0},{"id":"2421504013","title":"Mineralys Therapeutics files for $500M mixed shelf offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2421504013","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421504013?lang=en_us&edition=fundamental","pubTime":"2024-03-21 23:04","pubTimestamp":1711033452,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  Thursday filed a prospectus related to a mixed shelf offering of up to $500M.This prospectus is not an offer to sell these securities.More on Mineralys Therapeutics  Mineralys Therapeutics: A Story To Keep An Eye On Mineralys: 2nd Half 2024 Hypertension Data Readout Mineralys Therapeutics GAAP EPS of -$0.61 beats by $0.21 Mineralys Therapeutics stock jumps on $120M private placement financing Seeking Alpha’s Quant Rating on Mineralys Therapeutics","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4082169-mineralys-therapeutics-files-for-500m-mixed-shelf-offering","is_publish_highlight":false,"gpt_icon":0},{"id":"2421048306","title":"Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2421048306","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2421048306?lang=en_us&edition=fundamental","pubTime":"2024-03-21 21:11","pubTimestamp":1711026700,"startTime":"0","endTime":"0","summary":"Research and Development Expenses: Increased to $70.4 million for the year, reflecting investment in pivotal clinical trials.General and Administrative Expenses: Rose to $14.3 million annually due to the costs of operating as a public company and staff expansion.Net Loss: Grew to $71.9 million for the year, driven by higher R&D and G&A expenses.Cash Position: Strengthened with $239.0 million in cash, cash equivalents, and investments as of December 31, 2023.Mineralys Therapeutics has achieved several important milestones, including the initiation of the Launch-HTN trial, the second pivotal trial of lorundrostat. The company also began an open-label extension trial to collect additional safety and efficacy data. Furthermore, new data presented at the American Heart Association Scientific Sessions in Q4 2023 linked increased body mass index  with higher aldosterone production, highlighting the potential impact of lorundrostat on cardiorenal metabolic conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-inc-mlys-reports-131140865.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421201553","title":"Mineralys Therapeutics GAAP EPS of -$0.61 beats by $0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2421201553","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421201553?lang=en_us&edition=fundamental","pubTime":"2024-03-21 19:19","pubTimestamp":1711019949,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics press release : Q4 GAAP EPS of -$0.61  beats by $0.21. Cash, cash equivalents and investments were $239.0 million as of December 31, 2023, compared to $110.1 million as of December 31, 2022. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations, into 2026.    More on Mineralys Therapeutics  Mineralys Therapeutics: A Story To Keep An Eye On Mineralys: 2nd Half 2024 Hypertension Data Readout Mineralys Therapeutics stock jumps on $120M private placement financing Mineralys stock jumps 13% after first patient dosed in hypertension study Seeking Alpha’s Quant Rating on Mineralys Therapeutics","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4081960-mineralys-therapeutics-gaap-eps-of-0_61-beats-0_21","is_publish_highlight":false,"gpt_icon":0},{"id":"2421018170","title":"Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2421018170","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2421018170?lang=en_us&edition=fundamental","pubTime":"2024-03-21 19:03","pubTimestamp":1711019021,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.82) by 25.61 percent. This is a 64.94 percent increase over losses of $(1.74) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37866187/mineralys-therapeutics-q4-eps-0-61-beats-0-82-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2421132690","title":"Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2421132690","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2421132690?lang=en_us&edition=fundamental","pubTime":"2024-03-21 19:00","pubTimestamp":1711018800,"startTime":"0","endTime":"0","summary":"– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 –。– Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data –。RADNOR, Pa., March 21, 2024  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease  and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December31, 2023, and provided a corporate update.Expanded Management Team – Appointed Minji Kim, Ph.D. as Chief Business Officer. Dr. Kim brings more than two decades of experience in busi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-reports-fourth-quarter-110000741.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421094470","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2421094470","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2421094470?lang=en_us&edition=fundamental","pubTime":"2024-03-21 18:00","pubTimestamp":1711015200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Accenture Plc Class A                            2Q      2.66   6:44 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2420422558","title":"Mineralys Therapeutics: A Story To Keep An Eye On","url":"https://stock-news.laohu8.com/highlight/detail?id=2420422558","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420422558?lang=en_us&edition=fundamental","pubTime":"2024-03-18 19:04","pubTimestamp":1710759871,"startTime":"0","endTime":"0","summary":"Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels.The company's sole asset, lorundros","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1485376743/image_1485376743.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1485376743/image_1485376743.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4678840-mineralys-therapeutics-a-story-to-keep-an-eye-on","is_publish_highlight":false,"gpt_icon":0},{"id":"2419965786","title":"Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2419965786","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2419965786?lang=en_us&edition=fundamental","pubTime":"2024-03-14 04:05","pubTimestamp":1710360300,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., March 13, 2024  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease  and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.Participants can use the dial-in information above or choose the Call me option  for instant telephone access to the event which will be made active 15 minutes prior to the scheduled start time. A live webcast or replay of the conference call may be found here or on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.Media RelationsTom WeibleElixir Health Public RelationsPhone:  515-707-9678Email: tweible@elixirhealthpr.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-announce-fourth-quarter-200500673.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2410560950","title":"Mineralys: 2nd Half 2024 Hypertension Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2410560950","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2410560950?lang=en_us&edition=fundamental","pubTime":"2024-02-09 22:33","pubTimestamp":1707489191,"startTime":"0","endTime":"0","summary":"That's because results from this first phase 3 study are expected in the 2nd half of 2024. The primary endpoint is going to be a change in systolic blood pressure versus placebo after 12 weeks of treatment, which is measured by 24-hour ambulatory pressure monitoring. There is a difference between the two phase 3 studies to note. The LAUNCH-HTN study is using lorundrostat as an add on to existing background therapy. Whereas, the other ADVANCE-HTN study is using lorundrostat with standardized background therapy. The mov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4669031-mineralys-2nd-half-2024-hypertension-data-readout","is_publish_highlight":false,"gpt_icon":0},{"id":"2410033747","title":"Mineralys Therapeutics Announces Strategic Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2410033747","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2410033747?lang=en_us&edition=fundamental","pubTime":"2024-02-09 18:01","pubTimestamp":1707472895,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. (MLYS) has released an update to notify the public and investors about a regulation fd disclosure. Diving into the fin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-announces-strategic-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-announces-strategic-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.044},{"period":"1month","weight":0.053},{"period":"3month","weight":-0.0821},{"period":"6month","weight":1.0961},{"period":"1year","weight":-0.1571},{"period":"ytd","weight":0.5721}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}